How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Measuring—and delivering—what consumers really want by Eric Almquist, John Senior and Nicolas Bloch When customers evaluate a product or service, they weigh its perceived value against the asking ...

Micah Castelo is a web editor for EdTech: Focus on K-12. Her experience includes education and community news coverage for the Syracuse Post-Standard and international news reporting for the Pulitzer ...